# EDGAR Filing Document

**Accession Number:** 0001077183
**File Stem:** 0001077183-25-000138
**Filing Date:** 2025-6
**Character Count:** 18773
**Document Hash:** d007442c3c561e8e9c264077486c40d4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001077183-25-000138.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001077183-25-000138

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**EFFECTIVENESS DATE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEOGENOMICS INC
- **CENTRAL INDEX KEY:** 0001077183
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 742897368
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288083
- **FILM NUMBER:** 251050482

**BUSINESS ADDRESS:**
- **STREET 1:** 9490 NEOGENOMICS WAY
- **CITY:** FORT MYERS
- **STATE:** FL
- **ZIP:** 33912
- **BUSINESS PHONE:** 2397680600

**MAIL ADDRESS:**
- **STREET 1:** 9490 NEOGENOMICS WAY
- **CITY:** FORT MYERS
- **STATE:** FL
- **ZIP:** 33912

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN COMMUNICATIONS ENTERPRISES INC
- **DATE OF NAME CHANGE:** 19990120

**As filed with the Securities and Exchange Commission on June 16, 2025**

**Registration No. 333-_______**

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549**

**__________________**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**__________________**

**NEOGENOMICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **74-2897368** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **9490 NeoGenomics Way**<br>**Fort Myers, Florida** | **33912** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**NeoGenomics, Inc. 2023 Equity Incentive Plan, as Amended**

(Full title of the plan)

**Anthony P. Zook<br>Chief Executive Officer <br>9490 NeoGenomics Way**

**Fort Myers, Florida 33912**

**Telephone: (239) 768-0600** 

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an "emerging growth company". See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;Large accelerated filer ☒ | Smaller reporting company ☐ |
| &nbsp;&nbsp;&nbsp;Non-accelerated filer ☐ | Emerging growth company ☐  |
| &nbsp;&nbsp;&nbsp;Accelerated filer ☐ | |
| &nbsp;&nbsp;&nbsp;(Do not check if a smaller | |
| &nbsp;&nbsp;&nbsp;reporting company) | |

---

If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 of NeoGenomics, Inc., a Nevada corporation (the "**Company**") pertains to 4,325,000 shares of Common Stock, par value $0.001 per share ("**Common Stock**"), which has been authorized for issuance under the NeoGenomics, Inc. 2023 Equity Incentive Plan, as amended (the "**Plan**"). The Plan was originally adopted in 2023 and was amended and subsequently approved on May 22, 2025. The Company previously registered 3,975,000 shares of Common Stock on a Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the "**SEC**") on June 1, 2023 (File No. 333-272335) (the "**Earlier Registration Statement**").

Pursuant to General Instruction E of Form S-8, the contents of the Earlier Registration Statement are incorporated by reference in this Registration Statement and made a part hereof.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933 (the **"Securities Act"**). In accordance with the rules and regulations of the SEC and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this registration statement on Form S-8 (this **"Registration Statement"**) or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

In accordance with General Instruction E to Form S-8, the contents of the Earlier Registration Statement, with respect to securities offered pursuant to the Plan, are hereby incorporated by reference.

The following documents have been previously filed by the Company with the SEC and are hereby incorporated by reference into this registration statement and shall be deemed a part hereof:

(a) The Annual Report of the Company on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 18, 2025;

(b) The Quarterly Report of the Company on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on April 29, 2025;

(c) our Current Reports on Form 8-K filed with the SEC on January 10, 2025 (as amended on March 31, 2025), January 15, 2025, March 18, 2025 (as amended on March 19, 2025), April 8, 2025 and May 27, 2025; and

(d) The description of our Common Stock contained in the registration statement on Form 8-A (Registration No. 000-54384), filed with the SEC under Section 12(g) of the Exchange Act on May 2, 2011, as updated by the description of our Common Stock set forth in the Prospectus Supplement to our Registration Statement No. 333-186067 filed with the SEC pursuant to Rule 424(b)(5) on February 28, 2013, and any amendment or report filed with the SEC for the purpose of updating the description.

In addition, all reports and other documents subsequently filed by the registrant pursuant to sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, except for information furnished under Item 2.02 or 7.01 of Current Report on Form 8-K, or exhibits related thereto, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of the filing of such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document which also is or is deemed to be

------

incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Any Current Report on Form 8-K that is furnished to the SEC but not filed with the SEC is not deemed incorporated by reference into this Registration Statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 5.1 | <u>[Opinion of Snell & Wilmer, L.L.P.](exhibit51snellwilmeropinio.htm)</u> |
| 23.1 | <u>[Consent of Deloitte & Touche LLP](exhibit231deloittetoucheco.htm)</u> |
| 23.2 | <u>[Consent of Snell & Wilmer, L.L.P. (incorporated from Exhibit 5.1)](exhibit51snellwilmeropinio.htm)</u> |
| 24.1 | <u>[Power of Attorney (included on signature page hereto)](#iab196bdd48eb408cb7d774029949db74_4)</u> |
| 99.1 | <u>[NeoGenomics, Inc. 2023 Equity Incentive Plan (incorporated by reference to Annex A to the Company's Proxy Statement pursuant to Section 14(a) of the Exchange Act filed with the SEC on April 7, 2023)](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001077183/000119312523095194/d443927ddef14a.htm)</u> |
| 99.2 | <u>[First Amendment of the NeoGenomics, Inc.](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[2023](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[Equity Incentive](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[Plan, as approved by the Company's stockholders on May](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[22](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[, 20](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[25](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[(incorporated by reference to Annex](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[A](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[of the Company's Proxy Statement on Form DEF 14A filed with the SEC on April](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[8](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[, 20](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[25](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)[)](https://www.sec.gov/ix?doc=/Archives/edgar/data/1077183/000107718325000068/neo-20250408.htm)</u> |
| 107 | <u>[Filing Fee Table](exfilingfees.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fort Myers, State of Florida, as of the 12th day of June 2025.

**NEOGENOMICS, INC.** 

---

| | |
|:---|:---|
| By: | */s/ Anthony P. Zook* |
| Name: | Anthony P. Zook |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

We, the undersigned officers and directors of NeoGenomics, Inc., do hereby constitute and appoint Anthony P. Zook our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite are necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated below:

------

---

| | | |
|:---|:---|:---|
| **Signatures** | **Title(s)** | **Date** |
| */s/ Anthony P. Zook* | Director and Chief Executive Officer | June 16, 2025 |
| Anthony P. Zook | (Principal Executive Officer) |  |
| */s/ Jeffrey S. Sherman* | Chief Financial Officer | June 16, 2025 |
| Jeffrey S. Sherman | (Principal Financial Officer) |  |
| */s/ Greg D. Aunan* | Senior Vice President & Chief Accounting Officer | June 16, 2025 |
| Greg D. Aunan | (Principal Accounting Officer) |  |
| */s/ Lynn A. Tetrault* | Chair of the Board | June 16, 2025 |
| Lynn A. Tetrault |  |  |
| */s/ Elizabeth A. Floegel* | Director | June 16, 2025 |
| Elizabeth A. Floegel |  |  |
| */s/ Dr. Neil Gunn* | Director | June 16, 2025 |
| Dr. Neil Gunn |  |  |
| */s/ Dr. Alison L. Hannah* | Director | June 16, 2025 |
| Dr. Alison L. Hannah |  |  |
| */s/ Stephen M. Kanovsky* | Director | June 16, 2025 |
| Stephen M. Kanovsky |  |  |
| */s/ Michael A. Kelly* | Director | June 16, 2025 |
| Michael A. Kelly |  |  |
| */s/ David B. Perez* | Director | June 16, 2025 |
| David B. Perez |  |  |
| */s/ Felicia Williams* | Director | June 16, 2025 |
| Felicia Williams |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107** 

**Calculation of Filing Fee Table** 

<u>Form S-8</u>

(Form Type)

<u>NeoGenomics, Inc.</u> 

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security**<br>**Class**<br>**Title** | **Fee<br>Calculation<br>Rule** | **Amount<br>Registered**<sup>(1)</sup> | **Proposed<br>Maximum<br>Offering<br>Price Per<br>Share**<sup>(2)</sup> | **Maximum<br>Aggregate**<br>**Offering Price**<sup>(2)</sup> | **Fee**<br>**Rate** | **Amount of<br>Registration<br>Fee** |
| Equity | Common Stock, $0.001 par value per share, reserved for issuance under the NeoGenomics, Inc. 2023 Equity Incentive Plan | Rule 457(c) and Rule 457(h) | 4325000 | $7.20 | $31140000 | $0.0001531 | $4767.53 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $31140000 |  | $4767.53 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $— |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $4767.53 |

---

(1) In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the " <u>Securities Act</u> "), this registration statement on Form S-8 (the " <u>Registration Statement</u> ") shall be deemed to cover any additional shares of Common Stock, $0.001 par value per share (the " <u>Common Stock</u> ") of NeoGenomics, Inc. (the " <u>Company</u> ") that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's Common Stock, as applicable.

(2) Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act based upon the average of the high and low sale prices of the Common Stock as reported on the Nasdaq Global Market on June 13, 2025.

## Exhibit 5.1

**Exhibit 5.1**

![snell1a.jpg](snell1a.jpg)

June 16, 2025

NeoGenomics, Inc.

9490 NeoGenomics Way

Fort Myers, Florida 33912

Re: Form S-8

Ladies and Gentlemen:

We have acted as your special counsel in connection with the registration statement filed on Form S-8 (the "Registration Statement") by NeoGenomics, Inc., a Nevada corporation (the "Company"), with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Securities Act"), for the registration of 4,325,000 shares of the Company's common stock, par value $0.001 per share, which may be issued pursuant to the Company's 2023 Equity Incentive Plan (the "EIP") and were authorized by the First Amendment of the EIP approved on May 22, 2025 (the "EIP Amendment"). The EIP and EIP Amendment will be referred to collectively in this letter as the "Plan." The shares of common stock registered under the Registration Statement are collectively referred to in this letter as the "Shares".

You have requested our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering this opinion, we have examined the Registration Statement, the Plan, the Company's articles of incorporation, as amended, and bylaws, as amended, the Current Report filed by the Company on Form 8-K with the Securities and Exchange Commission on May 27, 2025, and we have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates of public officials and, as to certain matters of fact that are material to our opinion, we have also relied upon certificates made by officers of the Company. In rendering our opinion, in addition to the assumptions that are customary in opinion letters of this kind, we have assumed the genuineness of signatures on the documents we have examined, the legal capacity and authority of the persons signing the documents we have examined, the conformity to authentic documents of all documents submitted to us as copies, and that the Company will have sufficient authorized and unissued shares of common stock available with respect to any of the Shares issued after the date of this letter. We have not verified any of these assumptions.

This opinion is rendered as of the date of this letter and is limited to matters of Nevada corporate law, including applicable provisions of the Nevada Constitution and reported judicial decisions interpreting those laws. We express no opinion as to the laws of any other state, the federal law of the United States, or the effect of any federal or state securities laws.

![snell2a.jpg](snell2a.jpg)

------

![snell3a.jpg](snell3a.jpg)

Based upon and subject to the foregoing, it is our opinion that the Shares were duly authorized for issuance by the Company and, when awarded and issued pursuant to the terms of the Plan, will be validly issued, fully paid, and nonassessable.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations under such act.

Very truly yours,

/s/ ![imagea.jpg](imagea.jpg)

Snell & Wilmer L.L.P.

## Exhibit 23.1

Exhibit 23.1

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 18, 2025, relating to the financial statements of NeoGenomics, Inc and the effectiveness of NeoGenomics, Inc internal control over financial reporting, appearing in the Annual Report on Form 10-K of NeoGenomics, Inc. for the year ended December 31, 2024.

*/s/ Deloitte & Touche LLP* 

San Diego, California

June 16, 2025

<br>